Abstract
The objective of high dose chemotherapy followed by hematopoietic stem cell rescue is to halt autoimmunity in patients with severe AI. Few patients have received this treatment to date and this report summarizes the activity of HCT for AI from centers in North and South America. One-hundred and ninety-eight patients who underwent HCT primarily for the treatment of AI, were reported to the CIBMTR from 1996-2005 from 43 centers. Most received an autologous HCT (autoHCT) (171 of 198). The most common indications for autoHCT were multiple sclerosis (MS) (45%), scleroderma (SSC) (35%) and systemic lupus erythematous (SLE) (8%).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
